Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity — Stella

Recruiting

Back to Carrier State trials

Trial locations(1 site)

United States

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Key details

Sponsor

Philip Polgreen

Collaborators

National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment target

~160 participants

Started

December 2021

Primary completion

July 2026

Age range

18 Years – 100 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov